Result of AGM, Alliance Pharma PLC, 2020-05-18






RNS Number : 2411N
Alliance Pharma PLC
18 May 2020
 

For immediate release

18 May 2020

 

 

 

 

ALLIANCE PHARMA PLC

(“Alliance” or the “Company”)


Result of AGM

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that at its Annual General Meeting held on 18 May 2020, all the resolutions, as set out in the Notice of Meeting, were duly passed on a poll.

 

The votes were as follows:

 

RESOLUTION

VOTES FOR

%

VOTES AGAINST

%

VOTES TOTAL

% OF ISC VOTED

VOTES WITHHELD

1

Report and Accounts

307,119,531

87.77

42,803,894

12.23

349,923,425

65.90

341,086










2

Re-elect D. Cook

348,362,753

99.46

1,894,143

0.54

349,923,425

65.96

7,615










3

Re-elect P. Butterfield

350,252,415

99.99

7,502

0.01

350,259,917

65.97

4,594










4

Re-elect A. Franklin

350,126,924

99.97

118,638

0.03

350,245,562

65.96

18,949










5

Re-elect N. Clifford

302,972,623

87.53

43,167,791

12.47

346,140,414

65.19

4,124,097










6

Re-elect J. LeCouilliard

349,230,711

99.71

1,014,851

0.29

350,245,562

65.96

18,949










7

Re-elect R. Jones

349,908,539

99.90

334,002

0.10

350,242,541

65.96

21,970










8

Re-appoint Auditor

350,203,002

99.99

35,502

0.01

350,238,504

65.96

26,007










9

Remuneration of Auditor

350,241,261

99.99

14,619

0.01

350,255,880

65.96

 

8,631










10

Allot shares

340,262,574

97.15

9,995,811

2.85

350,258,385

65.97

6,126










11

Disapply Pre-emption rights

297,541,849

84.95

52,716,536

15.05

350,258,385

 

65.97

 

6,126










12

New Articles

350,228,320

99.99

2,264

0.01

350,230,584

65.96

33,927

The number of the Group’s shares in issue as at the date of the meeting was 530,975,807 ordinary shares of 1p each.

Please note that each share carries one vote and that a ‘vote withheld’ is not a vote in law and has not been counted in the calculation of the proportion of the votes for and against the resolution. Any proxy appointments which gave discretion to the Chairman have been included in the ‘votes for’ total.

Chris Chrysanthou
Head of Legal & Company Secretary
18 May 2020

 

For further information:

 

Alliance Pharma plc                                                                                                                        + 44 (0) 1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk 

 

Buchanan                                                                                                                                         + 44 (0) 20 7466 5000

Mark Court / Hannah Ratcliff

 

Numis Securities Limited                                                                                                             + 44 (0) 20 7260 1000

Nominated Adviser: Freddie Barnfield / Huw Jeremy

Corporate Broking: James Black

 

Investec Bank plc                                                                                                                           +44 (0) 20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Tejas Padalkar

 

About Alliance Pharma

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.

We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 

END

 
 

RAGSFSFDAESSELI

Leave a Reply

Your email address will not be published.